91 331

Cited 6 times in

Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer

Authors
 Satoru Iwasa  ;  Kei Muro  ;  Satoshi Morita  ;  Young Suk Park  ;  Masato Nakamura  ;  Masahito Kotaka  ;  Tomohiro Nishina  ;  Hiroshi Matsuoka  ;  Joong Bae Ahn  ;  Keun-Wook Lee  ;  Yong Sang Hong  ;  Sae Won Han  ;  Sang-Hee Cho  ;  Dong-Sheng Zhang  ;  Wei-Jia Fang  ;  Li Bai  ;  Xiang-Lin Yuan  ;  Ying Yuan  ;  Yasuhide Yamada  ;  Junichi Sakamoto  ;  Tae Won Kim 
Citation
 CANCER SCIENCE, Vol.112(11) : 4669-4678, 2021-11 
Journal Title
CANCER SCIENCE
ISSN
 1347-9032 
Issue Date
2021-11
MeSH
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols / adverse effects ; Antineoplastic Combined Chemotherapy Protocols / therapeutic use* ; Bevacizumab / therapeutic use ; Camptothecin / adverse effects ; Camptothecin / analogs & derivatives* ; Camptothecin / therapeutic use ; Colorectal Neoplasms / drug therapy* ; Colorectal Neoplasms / genetics ; Colorectal Neoplasms / mortality ; Colorectal Neoplasms / pathology ; Confidence Intervals ; Deoxycytidine / adverse effects ; Deoxycytidine / analogs & derivatives* ; Deoxycytidine / therapeutic use ; Female ; Fluorouracil / adverse effects ; Fluorouracil / analogs & derivatives* ; Fluorouracil / therapeutic use ; Genotype* ; Glucuronosyltransferase / genetics* ; Humans ; Leucovorin / adverse effects ; Leucovorin / therapeutic use ; Male ; Middle Aged ; Prognosis ; Progression-Free Survival ; Topoisomerase I Inhibitors / adverse effects ; Topoisomerase I Inhibitors / therapeutic use* ; Treatment Outcome ; Young Adult
Keywords
UGT1A1 ; XELIRI ; capecitabine ; colorectal cancer ; irinotecan
Abstract
The phase III AXEPT study showed the noninferiority of modified capecitabine plus irinotecan (mXELIRI) with or without bevacizumab relative to fluorouracil, leucovorin, and irinotecan (FOLFIRI) with or without bevacizumab as a second-line treatment for metastatic colorectal cancer. We evaluated the associations between the UGT1A1 genotype linked to adverse events-caused by irinotecan-and the efficacy and safety of mXELIRI and FOLFIRI. The UGT1A1 genotype was prospectively determined and patients were categorized into three groups according to WT (*1/*1), single heterozygous (SH; *28/*1 or *6/*1), and double heterozygous or homozygous (DHH; *28/*28, *6/*6, or *28/*6). Overall survival (OS), progression-free survival, response rate, and safety were assessed. The UGT1A1 genotype was available in all 650 randomized patients (WT, 309 [47.5%]; SH, 291 [44.8%]; DHH, 50 [7.7%]). The median OS was 15.9, 17.7, and 10.6 months in the WT, SH, and DHH groups, respectively, with an adjusted hazard ratio (HR) of 1.53 (95% confidence interval [CI], 1.12-2.09; P = .008) for DHH vs WT or SH. The median OS in the mXELIRI and FOLFIRI arms was 18.1 vs 14.3 months (HR 0.80; 95% CI, 0.62-1.03) in the WT group, 16.3 vs 18.3 months (HR 1.04; 95% CI, 0.79-1.36) in the SH group, and 13.0 vs 9.1 months (HR 0.71; 95% CI, 0.39-1.31) in the DHH group, respectively. Modified capecitabine plus irinotecan with or without bevacizumab could be a standard second-line chemotherapy in terms of efficacy and safety regardless of the UGT1A1 genotype.
Files in This Item:
T999202294.pdf Download
DOI
10.1111/cas.15092
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Ahn, Joong Bae(안중배) ORCID logo https://orcid.org/0000-0001-6787-1503
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/191121
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links